Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Albireo Ltd.
Just nine drug developers went public in the US during the first quarter of last year, but with the industry boosted by pandemic response, 32 biopharma companies launched IPOs in Q1 of this year.
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Plus deals involving Sanofi/SIRION, Merck KGAA/Day One, Beijing Tide/Graviton, Vaccinex/Surface Oncology, Athena/Tris, Biomunex/Onward, Cellectis/Cytovia
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.
- Medical Devices
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Biodel, Inc.
- Albireo AB